On July 28, 2020, Resverlogix participated in the Epigenetic Therapeutic Targets Virtual Summit, with an oral presentation by Dr. Norman Wong, titled: "Selective Bromodomain Inhibition with the Bromodomain and Extraterminal Domain (BET) Inhibitor Apabetalone: Discovery to Phase 3 Cardiovascular Outcomes Study." Presentation can be accessed here.
https://www.resverlogix.com/upload/media_element/215/a92c88143fe9/2020-07-28-epigenetic-therapeutic-targets---wong.pdf